eligibility_summary
Eligible: adults (≥18) with R/R large/high‑grade or transformed B‑cell lymphoma or FL3B after ≥1 prior anti‑CD20+chemo, ECOG ≤2, adequate counts/labs (allow lower if marrow involvement), contraception, consent. Exclude: prior severe irAEs, MAS/HLH, transplant (allo‑SCT/solid organ), recent RT or CAR‑T (<30d), CNS lymphoma/major CNS dz, unresolved tox >G1, recent immunosuppression, serious/active infection (HBV/HCV/HIV/EBV/PML), live vaccines, active autoimmune dz (exceptions), major comorbidity, recent surgery, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05464329 tests mosunetuzumab plus platinum-based salvage chemotherapy in relapsed/refractory aggressive B‑cell lymphoma. Mosunetuzumab (RO7030816/BTCT4465A) is a CD20×CD3 bispecific antibody (T‑cell–engaging IgG) that binds CD20 on malignant B cells and CD3 on T cells to trigger targeted T‑cell cytotoxicity. Two arms: mosunetuzumab + DHAX or mosunetuzumab + ICE. DHAX/ICE are cytotoxic regimens, key mechanisms include DNA crosslinking by platinum agents (e.g., oxaliplatin or carboplatin), alkylation (ifosfamide), antimetabolite blockade of DNA synthesis (high‑dose cytarabine), topoisomerase II inhibition (etoposide), and corticosteroid effects (dexamethasone). Targets/pathways: CD20 on B cells, CD3 on T cells (immune synapse/T‑cell activation), and DNA replication/repair in rapidly dividing lymphoma cells.